{
    "clinical_study": {
        "@rank": "151471", 
        "arm_group": {
            "arm_group_label": "Human immunoglobulin intravenous", 
            "arm_group_type": "Experimental", 
            "description": "Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance."
        }, 
        "brief_summary": {
            "textblock": "Human immunoglobulin (Ig) is the most commonly used blood product. It has been well-defined\n      the efficacy in patients with immunodeficiencies, Kawasaki disease, asthma and other immune\n      diseases. It is expected that Ig 10% will improve the usefulness and safety profile compared\n      to Ig 5% because it is expected the reduced hospitalization/treatment duration and less\n      adverse events related to volume overload."
        }, 
        "brief_title": "An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "GC5107A (IV-Globulin SN Inj. 10%) is a polyvalent intravenous human immunoglobulin G\n      preparation. It is prepared from plasma collected from more than 1000 healthy blood donors\n      and it expresses the large spectrum of antibody specificity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Given written informed consent\n\n          -  Male or female aged \u2265 19\n\n          -  Primary immune thrombocytopenia (ITP)\n\n          -  Platelet <20x10^9 /L\n\n          -  Patients who have taken adrenal cortical hormones and/or other immunosuppressive\n             medications should maintain their stable doses before and during this study\n\n        Exclusion Criteria:\n\n          -  Patients who have participate in other interventional study within 30 days\n\n          -  Inability in written/verbal communication\n\n          -  Engaged with an elective surgery\n\n          -  Pregnant or breast-feeding women\n\n          -  Women of childbearing potential who do not agree with contraception during this study\n\n          -  Patients who had experienced any hypersensitivity or shock with study drug or active\n             ingredient\n\n          -  Refractory to immunoglobulin therapy\n\n          -  Secondary immune thrombocytopenia\n\n               -  HIV-associated ITP\n\n               -  Lupus-associated ITP\n\n               -  Lymphproliferative disease\n\n               -  Hepatitis virus carrier\n\n               -  Other disease- or infection-associated ITP\n\n          -  Drug-Induced ITP\n\n          -  Hereditary thrombopenia (e.g., MYH9 disorders)\n\n          -  Hemolytic anemia (Positive direct Coomb's test)\n\n          -  Clinically significant abnormalities of immunoglobulin\n\n          -  Immunoglobulin A Deficiency\n\n          -  Immune disorders or deficiency\n\n          -  Alcohol or drug abuse within 6 months\n\n          -  Patients who had taken any medications which may effect platelet function or count\n             for at least 2 days prior study entry\n\n          -  Patients who had administrated with IVIg or anti-D immunoglobulin agents within 1\n             month\n\n          -  Patients who had undergone a splenectomy within 2 months\n\n          -  Clinically significant underlying disease or medical history at investigator's\n             discretion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063789", 
            "org_study_id": "GC5107A_P3"
        }, 
        "intervention": {
            "arm_group_label": "Human immunoglobulin intravenous", 
            "description": "After GC5107A Intravenous injection, evaluate platelet increase", 
            "intervention_name": "Human immunoglobulin intravenous", 
            "intervention_type": "Drug", 
            "other_name": "GC5107A (IV-Globulin SN Inj. 10%)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immune Thrombocytopenia", 
            "Immune Thrombocytopenic Purpura", 
            "Idiopathic Thrombocytopenic Purpura", 
            "Human Immunoglobulin", 
            "ITP", 
            "IVIg", 
            "IgIV", 
            "IV-Globulin SN Inj."
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chungnam National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ik-Chan Song, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Deagu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Daegu Catholic University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Sung Hwa Bae, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwasun", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chonnam National University Hwasun Hospital"
                }, 
                "investigator": {
                    "last_name": "Yeo-Kyeoung Kim, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chonbuk National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ho-Young Yhim, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "investigator": {
                    "last_name": "Soo Mee Bang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "CHA Budang Medical Center"
                }, 
                "investigator": {
                    "last_name": "Doyeun Oh, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Chul Won Jung, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "VHS Medical Center"
                }, 
                "investigator": {
                    "last_name": "Seung-Hyun Nam, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Inho Kim, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Soon Chung Hyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Kyoung Ha Kim, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ewha Womans University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Yeung-Chul Mun, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP).", 
        "other_outcome": {
            "description": "Day 1(pre-dosing, post dosing), 2 (pre-dosing, post dosing), 4, 8, 15, 29, and 85", 
            "measure": "Pharmacokinetics of GC5107A", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after intervention"
        }, 
        "overall_contact": {
            "email": "lsk220@greencross.com", 
            "last_name": "Seongkyung Lee", 
            "phone": "82-31-260-9075"
        }, 
        "overall_contact_backup": {
            "email": "jhsong@symyoo.com", 
            "last_name": "Ji-Hyun Song, Ph.D.", 
            "phone": "82-70-4335-4754"
        }, 
        "overall_official": [
            {
                "affiliation": "CHA Bundang Medical Center", 
                "last_name": "Doyeun Oh, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Green Cross Corporation", 
                "last_name": "Chang-Hee Lee, M.D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "% of patients who achieved the platelet count \u2265 50 x 10^9/L increase", 
            "safety_issue": "No", 
            "time_frame": "within 7 days after intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063789"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration from the achievement of platelet count \u2265 50 x 10^9/L increase to the loss", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "Response (R): platelet count  \u2265 30 x 10^9/L and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding.", 
                "measure": "% patient with response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "Complete response (CR):  platelet count >100 x 10^9/L, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding.", 
                "measure": "% patient with complete response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "measured from the achievement of R to loss of R", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "measured from the achievement of CR to loss of CR", 
                "measure": "Duration of complete response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "No response (NR): platelet count < 30 x 10^9/l or less than 2-fold increase of baseline platelet count, confirmed on at least 2 separate occasions approximately 1 day apart, or bleeding.", 
                "measure": "% patient with no response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "measure": "Descriptive statistics of platelet count at each visit", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "description": "Haemorrhage severity score (HSS) system", 
                "measure": "Haemorrhage severity rate at each visit", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "measure": "Quality of Life (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intevention"
            }, 
            {
                "measure": "Patient reported bleeding events", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after intervention"
            }, 
            {
                "description": "Rescue medications: Acetaminophen, antihistamines.", 
                "measure": "Usage of rescue mediations", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after intervention"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks after intervention"
            }, 
            {
                "measure": "Drug compliance", 
                "safety_issue": "No", 
                "time_frame": "2 days of intervention"
            }, 
            {
                "measure": "Viral safety", 
                "safety_issue": "Yes", 
                "time_frame": "Base line, 4 weeks and 12 weeks after intervention"
            }, 
            {
                "measure": "Time to the achievement of platelet count \u226550x10^9/L increase", 
                "safety_issue": "No", 
                "time_frame": "within 7 days after intervention"
            }
        ], 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}